SOA
ASBP

Sea Otter Advisors’s Aspire Biopharma ASBP Stock Holding History

Sea Otter Advisors’s Portfolio ASBP Stock Details ASBP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-1
Closed -$12.2K – 173
2023
Q4 		$12.2K Hold
1
– – 0.01% 123
2023
Q3 		$15.7K Buy
+1
New +$12.9K 0.01% 154

Other funds holding ASBP

FTCM
Fir Tree Capital Management New York $21.8M AUM 1.61% 1-Year Est. Return
PC
Periscope Capital Toronto, Ontario, Canada $902M AUM 6.51% 1-Year Est. Return
AI
Arena Investors Purchase, New York $12.5M AUM 0.27% 1-Year Est. Return
Hudson Bay Capital Management
Hudson Bay Capital Management Stamford, Connecticut $29B AUM 30.2% 1-Year Est. Return
AA
AQR Arbitrage Greenwich, Connecticut $6.09B AUM 27.01% 1-Year Est. Return
EAM
Exos Asset Management New York $2.32K AUM 108.13% 1-Year Est. Return
LP
LMR Partners London, United Kingdom $45.4B AUM 60.68% 1-Year Est. Return
FTCM
First Trust Capital Management Chicago, Illinois $1.9B AUM 58.39% 1-Year Est. Return
CAC
Cowen and Company New York $2.97B AUM 105.26% 1-Year Est. Return
FPA
First Pacific Advisors El Segundo, California $7.14B AUM 21.51% 1-Year Est. Return

Sea Otter Advisors's ASBP Position: Q1 2024 in Review

Sea Otter Advisors sold out of Aspire Biopharma (ASBP) in Q1 2024, closing a stake of 1 share — an estimated $12.2K sold.

Sea Otter Advisors first reported a position in ASBP in Q3 2023 and held it in 2 quarters. The position peaked at $15.7K in Q3 2023. 17 funds tracked by Wall St. Rank hold ASBP as of Q1 2024.

  • Sea Otter Advisors reported no remaining Aspire Biopharma position as of Q1 2024 after selling out during the quarter.
  • Sea Otter Advisors sold 1 Aspire Biopharma share in Q1 2024, an estimated $12.2K.
  • Sea Otter Advisors first reported a position in Aspire Biopharma in Q3 2023 and held it in 2 quarters.
  • Sea Otter Advisors's Aspire Biopharma position peaked at $15.7K in Q3 2023.
  • 17 funds tracked by Wall St. Rank held Aspire Biopharma as of Q1 2024.

Based on Sea Otter Advisors's 13F filing for Q1 2024, filed 15 May 2024.